Tag Archives: Abbott

Without An Rx, Some Pharmas Are Skittish

By Ben Comer | Published: August 24, 2011
Lower margins and strong-arm direct-to-consumer campaigns are two of the primary barriers to selling nutraceuticals, according to a business school ‘war game’ conducted with the participation of Abbott, Danone (Dannon in the US), GSK and Nestlé. But the global nutraceuticals market – worth $80 billion in 2010, according to Frost & Sullivan – is expected [...]
Posted in Advertising, Global, IP, Marketing, Regulatory, Strategy, patient education | Also tagged , , | 4 Comments

Abbott Shells Out $3.7 Billion for Piramal

By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment

Saving Haiti: One Donation at a Time (UPDATED 1/21)

By George Koroneos | Published: January 15, 2010
Image by American Red Cross via Flickr It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
Posted in News | Also tagged , , , , , , , | 2 Comments

Abbott to Purchase Solvay for $6.6 Billion (Update 1)

By George Koroneos | Published: September 28, 2009
Abbott announced, early Monday morning, that it had signed a deal to purchase Belgium-based drug manufacturer Solvay Pharmaceuticals for $6.6 billion in cash—a mere five months after Solvay’s CEO Werner Cautreels announced that the company was searching for a proper suitor. The deal adds more than $3 billion in annualized sales to its global pharmaceutical business—three-quarters [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

AZ, Sepracor, and Abbott Cinch Belts With Layoffs

By George Koroneos | Published: January 29, 2009
It’s been a tough few days for pharmaceutical employees. Just days after Pfizer announced that it would eliminate 10 percent of its workforce, three other companies are revealing restructuring plans that include releasing hundreds (and in one case thousands) of employees. In its fourth quarter report released today, AstraZeneca stated that it will continue its “new [...]
Posted in People, Strategy | Also tagged , , , | 1 Comment